Proteasome inhibitor prevents experimental arterial thrombosis in renovascular hypertensive rats

Justyna K. Ostrowska; Marek Z.Wojtukiewicz; Ewa Chabielska; Wlodzimierz Buczko; Halina Ostrowska

doi:10.1160/TH03-11-0707

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 2004; 92(01): 171-177
DOI: 10.1160/TH03-11-0707

Cell Signalling and Vessel Remodelling

Schattauer GmbH

Proteasome inhibitor prevents experimental arterial thrombosis in renovascular hypertensive rats

Justyna K. Ostrowska

¹Department of Oncology, Medical University of Bialystok, Poland

,

Marek Z.Wojtukiewicz

¹Department of Oncology, Medical University of Bialystok, Poland

,

Ewa Chabielska

²Department of Biopharmacy, Medical University of Bialystok, Poland

,

Wlodzimierz Buczko

³Department of Pharmacodynamics, Medical University of Bialystok, Poland

,

Halina Ostrowska

⁴Department of Biology, Medical University of Bialystok, Poland

› Institutsangaben

Abstract

Summary

Recent studies indicate that highly selective proteasome inhibitors can be useful in prevention of some cardiovascular events. Here we demonstrate that proteasome inhibitor, Z-IleGlu (Ot-Bu) Ala-Leucinal (PSI), is active in the prevention of platelet-dependent arterial thrombosis induced in renovascular hypertensive rats (two-kidney, one clip Goldblatt model, and 2K1C, n=5).The administration of PSI intravenously at a single dose of 0.3 mg/kg before induction of arterial thrombosis markedly increased carotid final flow rate, as compared to control (vehicle) group (10.36 ± 1.8 ml/min and 1.2 ± 1.2 ml/min, respectively), significantly decreased the wet (1.23 ± 0.23 mg and 4.1 ± 0.94 mg, respectively), and dry (0.46 ± 0.145 mg and 1.46 ± 0.39, respectively) thrombus weight, and completely prevented arterial occlusion. Moreover, platelets from PSI treated thrombotic 2K1C rats, showed in response to collagen a significant inhibition of aggregation in the whole blood (10.26 ± 0.6 ohms vs. 15.51 ± 0.91ohms in the control group). In contrast, collagen-induced platelet aggregation was not inhibited in vitro, after pre-treatment of the blood with PSI at the concentration of 10μM that effectively inhibited the 20S proteasome activity in platelets, indicating that ex vivo anti-aggregatory effect of PSI proceeds through an indirect mechanism not associated with suppression of 20S proteasome activity in platelets. In conclusion, our in vivo findings demonstrate that proteasome inhibitor, Z-Ile-Glu(Ot-Bu)Ala-Leucinal, prevents the development of arterial thrombosis in renovascular hypertensive rats and effectively suppresses platelet aggregation by an indirect mechanism. Thus the data provide a new insight into the potential role for the proteasome-dependent pathway in cardiovascular events.

Keywords

Arterial thrombosis - platelet aggregation - proteasome inhibitor - renovascular hypertension - rat

Volltext

Referenzen

References
1 Coux O, Tanaka K, Goldberg AL. Structure and function of the 20S and 26S proteasomes. Annu Rev Biochem 1996; 65: 801-47.
2 Lee DH, Goldberg AL. Proteasome inhibitors: valuable new tools for cell biologists. Trends Cell Biol 1998; 08: 397-403.
3 Palombella VJ, Rando OJ, Goldberg AL. et al. The ubiquitin-proteasome pathway is required for processing the NF-kB precursor protein and the activation of NF-kB. Cell 1994; 78: 773-85.
4 Schwartz AL, Ciechanover A. The ubiquitinproteasome pathway and pathogenesis of human diseases. Annu Rev Med 1999; 50: 57-74.
5 Meng L, Mohan R, Kwok BHB. et al. Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo anti-inflammatory activity. Proc Natl Acad Sci USA 1999; 96: 10403-408.
6 Adams J. Proteasome inhibition: a novel approach to cancer therapy. Trends Mol Med 2002; 08: 49-54.
7 Read MA, Neish AS, Luscinskas FW. et al. The proteasome pathway is required for cytokine-induced endothelial-leukocyte adhesion molecule expression. Immunity 1995; 02: 493-9.
8 Conner EM, Brand S, Davis JM. et al. Proteasome inhibition attenuates nitric oxide synthase expression, VCAM-1 transcription and the development of chronic colitis. J Pharmacol Exp Ther 1997; 282: 1615-22.
9 Xia L, Pan J, Yao L. et al. A proteasome inhibitor, an antioxidant, or a salicylate, but not a glucocorticoid, blocks constitutive and cytokine-inducible expression of P-selectin in human endothelial cells. Blood 1998; 91: 1625-32.
10 Okamoto H, Takaoka M, Ohkita M. et al. Proteasome inhibitor lessens the increased aortic endothelin-1 content in deoxycorticosterone acetate-salt hypertensive rats. Eur J Pharmacol 1998; 350: 11-12.
11 Takaoka M, Itoh M, Kohyama S. et al. Proteasome inhibition attenuates renal endothelin-1 production and the development of ischemic acute renal failure in rats. J Cardivasc Pharmacol 2000; 36: 225-7.
12 Campbell B, Adams J, Shin YK. et al. Cardioprotective effects of a novel proteasome inhibitor following ischemia and reperfusion in the isolated perfused rat heart. J Mol Cell Cardiol 1999; 31: 467-76.
13 Phillips JB, Williams AJ, Adams J. et al. Proteasome inhibitor PS519 reduces infarction and attenuates leukocyte infiltration in a rat model of focal cerebral ischemia. Stroke 2000; 31: 1686-93.
14 Zhang L, Zheng ZG, Zhang RL. et al. Postischemic (6-hour) treatment with recombinant human tissue plasminogen activator and proteasome inhibitor PS-519 reduces infarction in a rat model of embolic focal cerebral ischemia. Stroke 2001; 32: 2926-31.
15 Cines DB, Pollak ES, Buck CA. et al. Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood 1998; 91: 3527-61.
16 Lip GY, Li-Saw-Hee FL. Does hypertension confer a hypercoagulable state?. J Hypertens 1998; 16: 913-6.
17 Brown NJ, Vaughan DE. Prothrombotic effects of angiotensin. Adv Inter Med 2000; 45: 419-29.
18 Huang WC, Ploth DW, Bell PD. et al. Bilateral renal function responses to converting enzyme inhibitor (SQ 20,881) in two-kidney, one clip Goldblatt hypertensive rats. Hypertension 1981; 03: 285-93.
19 Guarini S. A highly reproducible model of arterial thrombosis in rats. J Pharmacol Toxicol Methods 1996; 35: 101-5.
20 Kawasaki T, Sato K, Sakai Y. et al. Comparative studies of an orally-active factor Xa inhibitor, YM-60828, with other antithrombotic agents in a rat model of arterial thrombosis. Thromb Haemost 1998; 79: 410-6.
21 Schumacher WA, Steinbacher TE, Heran CL. et al. Effects of antitrombotic drugs in rat model of aspirin-insensitive arterial thrombosis. Thromb Haemost 1993; 69: 509.
22 Zatz R. An Iow cost tail-cuff method for he estimation of mean arterial pressure in unconscious rats. Lab Anim Sci 1990; 40: 198-201.
23 Giles AR. Guidelines for the use of animal in biomedical research. Thromb Haemost 1987; 58: 1078-84.
24 Adams J, Palombella VJ, Sausville EA. et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 1999; 59: 2615-22.
25 Wilsoncroft PS, Lofts FJ, Griffiths RJ. et al. The effect of 6-oxo-PGE1 on human platelet aggregation in whole blood in vitro. J Pharm Pharmacol 1985; 37: 139-41.
26 Shibatani W, Ward F. Sodium dodecyl sulfate (SDS) activation of the 20S proteasome in rat liver. Arch Biochem Biophys 1995; 321: 160-6.
27 Wilk S, Figueiredo-Pereira ME. Synthetic inhibitors of the multicatalytic proteinase complex (proteasome). Enzyme Protein 1993; 47: 306-13.
28 Ostrowska H, Ostrowska JK, Worowski K. et al. Human platelet 20S proteasome: inhibition of its chymotrypsin-like activity and identification of the proteasome activator PA28. A preliminary report. Platelets 2003; 14: 151-7.
29 Yukawa M, Sakon M, Kambayashi I. et al. Proteasome and its novel endogenous activator in human platelets. Biochem Biophys Res Commun 1991; 178: 256-62.
30 Cobb RR, Felts KA, Parry GC. et al. Proteasome inhibitors block VCAM-1 and ICAM-1 gene expression in endothelial cells without affecting nuclear translocation of nuclear factor kappa B. Eur J Pharmacol 1996; 264: 839-45.
31 Collins T, Read MA, Neish AS. et al. Transcriptional regulation of endothelial cell adhesion molecules: NF-κB and cytokineinducible enhancers. FASEB J 1995; 09: 899-909.
32 Morgan EN, Pohlman TH, Vocelka C. et al. Nuclear factor kappa B mediates a procoagulant response in monocytes during extracorporeal circulation. J Thorac Cardiovasc Surg 2003; 125: 165-71.
33 Ruf W, Edgington TS. Structural biology of tissue factor, the initiator of thrombogenesis in vivo. FASEB J 1994; 08: 385-90.
34 Campbell DJ. The renin-angiotensin and the kallikrein-kinin systems. Int J Biochem Cell Biol 2003; 35: 784-91.
35 Napoleone E, Di Santo A, Camera M. et al. Angiotensin-converting enzyme inhibitors downregulate tissue factor synthesis in monocytes. Circ Res 2000; 86: 139-43.
36 Ridker PM, Gaboury CL, Conlin PR. et al. Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II: evidence of a potential interaction between the reninangiotensin system and fibrynolitic function. Circulation 1993; 87: 1968-73.
37 Pueyo ME, Gonzales W, Nicoletti A. et al. Angiotensin II stimulates endothelial vascular cell adhesion molecule-1 via nuclear factor-κB activation induced by intracellular oxidative stress. Arterioscler Thromb Vasc Biol 2000; 20: 645-51.
38 Pastor L, Tessitor A, Martinotti S. et al. Angiotensin II stimulates intracellular adhesion molecule-1 (ICAM-1) expression by human vascular endothelial cells and increases soluble ICAM-1 release in vivo. Circulation 1999; 100: 1646-52.
39 Kranzhofer R, Browatzki M, Schmidt J, Kubler W. Angiotensin II activates the proinflammatory transcription factor nuclear factor-κB in human monocytes. Biochem Biophys Res Commun 1999; 257: 826-8.
40 Ruitz-Ortega M, Lorenzo O, Ruperez M. et al. Angiotensin II activates nuclear transcription factor κB through AT1 and AT2 in vascular smooth muscle. Circ Res 2000; 86: 1266-72.